for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Idera Pharmaceuticals Inc

IDRA.OQ

Latest Trade

1.01USD

Change

-0.01(-0.98%)

Volume

161,747

Today's Range

1.00

 - 

1.05

52 Week Range

1.00

 - 

6.11

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
1.02
Open
1.03
Volume
161,747
3M AVG Volume
64.73
Today's High
1.05
Today's Low
1.00
52 Week High
6.11
52 Week Low
1.00
Shares Out (MIL)
42.26
Market Cap (MIL)
46.48
Forward P/E
-1.48
Dividend (Yield %)
--

Next Event

Idera Pharmaceuticals Inc Annual Shareholders Meeting

Latest Developments

更多

Idera Pharmaceuticals Announces Results From ILLUMINATE-301 Trial Of Tilsotolimod + Ipilimumab In Anti-PD-1 Refractory Advanced Melanoma

Idera Pharmaceuticals Posts Q4 Loss Per Share $2.11

Idera Pharmaceuticals Reports Third Quarter Financial Results And Provides Corporate Update

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Idera Pharmaceuticals Inc

Idera Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of therapeutics for oncology and rare diseases. The Company utilizes two drug discovery technology platforms to design and develop drug candidates, which include Toll-like receptor (TLR) targeting technology and third-generation antisense (3GA) technology. Using TLR technology, the Company designs synthetic oligonucleotide-based drug candidates to act by modulating the activity of specific TLRs. Using its 3GA technology, the Company is developing drug candidates to turn off the messenger ribo nucleic acid (mRNA) associated with disease causing genes. The Company's drug candidates include IMO-8400, IMO-2125 and IMO-9200. The Company has designed TLR antagonists and agonists to act by modulating the activity of targeted TLRs. It is developing its 3GA technology to turn off the mRNA associated with disease causing genes.

Industry

Biotechnology & Drugs

Contact Info

505 Eagleview Blvd Ste 212

EXTON, PA

19341-1199

United States

+1.484.3481600

http://www.iderapharma.com/

Executive Leadership

james A. Geraghty

Independent Chairman of the Board

Vincent J. Milano

President, Chief Executive Officer, Director

John J. Kirby

Chief Financial Officer, Senior Vice President

Daniel B. Soland

Chief Operating Officer, Senior Vice President

Bryant David Lim

Senior Vice President, General Counsel, Corporate Secretary

Key Stats

3.00 mean rating - 4 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

0.0K

2019

0.0K

2020

0.0K

2021(E)

0.0K
EPS (USD)

2018

-2.250

2019

-2.960

2020

-3.330

2021(E)

-0.743
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
--
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
--
LT Debt To Equity (MRQ)
--
Return on Investment (TTM)
-794.96
Return on Equity (TTM)
-250.67

Latest News

Latest News

BRIEF-Idera Pharmaceuticals Reports Q1 Loss Per Share $0.10

* IDERA PHARMACEUTICALS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

BRIEF-Idera Pharmaceuticals Enters Into A Clinical Development Support Agreement With Pillar Partners Foundation

* IDERA PHARMACEUTICALS ENTERS INTO A CLINICAL DEVELOPMENT SUPPORT AGREEMENT WITH PILLAR PARTNERS FOUNDATION TO EXPAND THE CLINICAL RESEARCH ON IMO-2125 BEYOND PD-1 REFRACTORY MELANOMA

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up